AI's Drug Design Dream Hits a 40% Snag!
“LLMs still need a prescription for improvement in drug discovery.”
The story behind the toon
What happened: Researchers introduced SMDD-Bench for LLMs in drug design. The benchmark includes 502 multi-turn drug design tasks across 5 categories. The top model, GPT5.4, was tested against the benchmark. GPT5.4 solved only 40.2% of tasks, highlighting major gaps.
This Neural Toon is based on the story “SMDD-Bench: Can LLMs Solve Real-World Small Molecule Drug Design Tasks?”.
Read our summary of the story · original source
Comic transcript
Panel 1 – Sam: SMDD-BENCH! AI DRUG DESIGN! TOTAL REVOLUTION!
Panel 1 – Casey: A new benchmark? For LLMs?
Panel 1 – Fact: Researchers introduced SMDD-Bench for LLMs in drug design.
Panel 2 – Sam: 502 COMPLEX TASKS! ULTIMATE DISRUPTION!
Panel 2 – Casey: Multi-turn drug design tasks, quite specific.
Panel 2 – Fact: The benchmark includes 502 multi-turn drug design tasks across 5 categories.
Panel 3 – Sam: GPT5.4 ON THE BENCH! AI WILL CURE ALL!
Panel 3 – Casey: The leading model, naturally.
Panel 3 – Fact: The top model, GPT5.4, was tested against the benchmark.
Panel 4 – Sam: AI IS UNSTOPPABLE! MEDICAL BREAKTHROUGH!
Panel 4 – Casey: It solved 40.2%. Gaps remain.
Panel 4 – Fact: GPT5.4 solved only 40.2% of tasks, highlighting major gaps.
More Neural Toons · Neural Snaps · The Neural Feed
📬 Get the top AI stories every morning
One email a day, no spam, unsubscribe anytime.